Cover Image

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton...

Full description

Saved in:

Bibliographic Details
Main Authors:	Upreti VV (Author), Song Y (Author), Wang J (Author), Byon W (Author), Boyd RA (Author), Pursley JM (Author), LaCreta F (Author), Frost CE (Author)
Format:	Book
Published:	Dove Medical Press, 2013-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
by: Frost C, et al.
Published: (2018)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
by: Frost C, et al.
Published: (2017)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
by: Persson PB
Published: (2015)

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
by: Anis TR, et al.
Published: (2021)

Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxaban
by: E. V. Titaeva, et al.
Published: (2020)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020)

Efficacy and Toxicity of Factor Xa Inhibitors
by: Maryna Bondarenko, et al.
Published: (2013)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
by: Cui Y, et al.
Published: (2013)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
by: Samira J. Merali, et al.
Published: (2023)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014)

Discovery and development of Factor Xa inhibitors (2015-2022)
by: Wei Zheng, et al.
Published: (2023)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
by: Elise Carpenter, et al.
Published: (2019)

Preparation and evaluation of famotidine nanosuspension
by: Marwa M. Malik, et al.
Published: (2018)

THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE
by: A. V. Kryukov, et al.
Published: (2016)

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa
by: Go Oun Kim, et al.
Published: (2023)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
by: Holly Mansell, et al.
Published: (2022)

Assessment of omeprazole and famotidine effects on the pharmacokinetics of tacrolimus in patients following kidney transplant-randomized controlled trial
by: Miłosz Miedziaszczyk, et al.
Published: (2024)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
by: Juseung Lee, et al.
Published: (2023)

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
by: Robert W. Malone, et al.
Published: (2021)

Development and evaluation of novel-trans-buccoadhesive films of famotidine
by: M Alagusundaram, et al.
Published: (2011)

CONSIDERING QUESTION OF SAFETY OF DIRECT ORAL ANTICOAGULANTS: THE RESULTS OF THE COMPARISON OF APIXABAN AND WARFARIN
by: Igor S. Yavelov
Published: (2018)

Kinetic investigation of Famotidine S-oxidation reaction using potassium caroate. Development and validation of the titrimetric method for the quantitative determination of Famotidine in pure substance and medical preparation
by: Blazheyevskiy Mykola Yevstahiyovych, et al.

Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions
by: Long Meng, et al.
Published: (2022)

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
by: Frédéric Gaspar, et al.
Published: (2023)

Quality-by-Design-Driven Nanostructured Lipid Scaffold of Apixaban: Optimization, Characterization, and Pharmacokinetic Evaluation
by: Kiran Patil, et al.
Published: (2024)

Effects of famotidine use during pregnancy: an observational cohort study
by: Ayako Nishimura, et al.
Published: (2024)

A Pulsatile Tablet of Famotidine Using Core in Cup Method.
by: Shreya Ajay Rajguru, et al.
Published: (2023)

Formulation development and characterization of famotidine dry suspension for oral use
by: Sajjad Qaisar, et al.
Published: (2022)

TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1
by: Emiko Shinozawa, et al.
Published: (2018)

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke
by: Kryukov AV, et al.
Published: (2018)

Tizanidine-induced acute severe cystitis in a female taking famotidine
by: Poudel RR, et al.
Published: (2015)

Novel swellable polymer of orchidaceae family for gastroretentive drug delivery of famotidine
by: Razavi M, et al.
Published: (2014)

Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm
by: Huan Yang, et al.
Published: (2022)

Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells
by: Jin Huang, et al.
Published: (2021)

Characterization of thrombin/factor Xa inhibitors in Rhizoma Chuanxiong through UPLC-MS-based multivariate statistical analysis
by: Yi-Yao Yang, et al.
Published: (2020)

POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT INHIBIT XA-FACTOR
by: A. D. Erlich
Published: (2019)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
by: Mohamed F. Zaky, et al.
Published: (2023)